Connect your AI

Organon OGN Short-term debt and current portion of long-term debt

Short-term debt and current portion of long-term debt at other companies

Bristol-Myers SquibbBMY

$2.31B-35.1%

PfizerPFE

——

The Cooper Companies, Inc.COO

——

ViatrisVTRS

——

Merck & Co.MRK

——

KenvueKVUE

——

Other financials

Income statement

Revenue$1.5B-3.5%

Gross profit$783.0M-6.9%

Net income$146.0M+67.8%

EPS (diluted)$0.55+66.7%

Balance sheet

Cash & equivalents$1.1B+104%

Total debt$8.6B-4.3%

Total equity$903.0M+66.6%

Total assets$13.0B-1.2%

Cash flow

Operating cash flow$225.0M+200%

CapEx$37.0M+15.6%

Free cash flow$188.0M+337%

Valuation

Market cap$3.53B-59.4%

Profitability

Gross margin52.8%-4.4pp

Net margin8%-12.3pp

FCF margin11.1%-1.3pp

Returns & leverage

Return on equity71.6%—

Debt / equity9.5×-7.0×

Current ratio2×+0.3×

Where this comes from

Reported directly by Organon in its filing.

Tagged under the XBRL concept us-gaap:DebtCurrent.

The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organon's short-term debt and current portion of long-term debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Organon's short-term debt and current portion of long-term debt?: Organon (OGN) reported short-term debt and current portion of long-term debt of $16M in Q1 2026.